

Appendix A

Claim Amendments

1. (Previously presented) A compound of formula 1,

- R1 is hydrogen, halogen, hydroxyl, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl, hydroxy-1-4C-alkyl or mono- or di-1-4C-alkylamino,
- R2 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, aryl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxycarbonyl, mono- or di-1-4C-alkylamino-1-4C-alkylcarbonyl, hydroxy-1-4C-alkyl, fluoro-2-4C-alkyl,
- R3 is hydrogen, halogen, fluoro-1-4C-alkyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-

alkyl, 1-4C-alkoxy-1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyl-N-1-4C-alkylamino, 1-4C-alkoxy-1-4C-alkylcarbonylamino or the group -CO-NR31R32,

where

R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and R32 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, hydroxypyrrolidino, aziridino, azetidino, piperidino, piperazino, N-1-4C-alkylpiperazino or morpholino group,

X is O (oxygen) or NH and

Ar is a mono- or bicyclic aromatic residue, substituted by R4, R5, R6 and R7, which is selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furyl, benzofuryl, thienyl, benzothienyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, chinolinyl and isochinolinyl,

wherein

R4 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxy, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, halogen, hydroxy, aryl, aryl-1-4C-alkyl, aryl-oxy, aryl-1-4C-alkoxy, trifluoromethyl, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl,

R5 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl or hydroxy,
R6 is hydrogen, 1-4C-alkyl or halogen and
R7 is hydrogen, 1-4C-alkyl or halogen,
and wherein

aryl is phenyl or substituted phenyl with one, two or three same or different substituents from the group of 1-4C-alkyl, 1-4C-alkoxy, carboxy, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxy and cyano,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

2. (Previously presented) A compound of formula 1 according to claim 1,

in which

- R1 is hydrogen, halogen, hydroxyl, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl, hydroxy-1-4C-alkyl or mono- or di-1-4C-alkylamino,
- R2 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, aryl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxycarbonyl, mono- or di-1-4C-alkylamino-1-4C-alkylcarbonyl, hydroxy-1-4C-alkyl, fluoro-2-4C-alkyl,
- R3 is hydrogen, halogen, fluoro-1-4C-alkyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32,

where

- R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and
- R32 is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkyl, alkoxy-1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, piperidino, piperazino, N-1-4C-alkylpiperazino or morpholino group,

X is O (oxygen) or NH and

Ar is a mono- or bicyclic aromatic residue, substituted by R4, R5, R6 and R7, which is selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furyl, benzofuryl, thienyl, benzothienyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, chinolinyl and isochinolinyl,

wherein

- R4 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxy, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, halogen, hydroxy, aryl, aryl-1-4C-alkyl, aryl-oxy, aryl-1-4C-alkoxy, trifluoromethyl, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl,
- R5 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy, alkoxycarbonyl, halogen, trifluoromethyl or hydroxy,

R6 is hydrogen, 1-4C-alkyl or halogen and R7 is hydrogen, 1-4C-alkyl or halogen, and wherein

aryl is phenyl or substituted phenyl with one, two or three same or different substituents from the group of 1-4C-alkyl, 1-4C-alkoxy, carboxy, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxy and cyano,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

3. (Previously presented) A compound of formula 1 according to claim 1,

- R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or fluoro-1-4C-alkyl,
- R2 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,
- R3 is hydrogen, halogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkyl, 1-4C-alkylcarbonyl-N-1-4C-alkylamino or the group -CO-NR31R32, where

R31 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and
R32 is hydrogen or 1-4C-alkyl,
or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, hydroxypyrrolidino, aziridino, azetidino, piperidino, piperazino, N-1-4C-alkylpiperazino or morpholino group,

- X is O (oxygen) or NH and
- Ar is a phenyl group, substituted by R4, R5, R6 and R7, wherein
 - R4 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxy, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, halogen, hydroxy, trifluoromethyl, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl,
 - R5 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, halogen, trifluoromethyl or hydroxy,
 R6 is hydrogen, 1-4C-alkyl or halogen and
 R7 is hydrogen, 1-4C-alkyl or halogen,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

4. (Previously presented) A compound according to claim 1, characterized by the formula 1a,

$$R3$$
 $R2$
 $R1$
 $R5$
 $R4$
 $R4$
 $R1$

in which

- R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or fluoro-1-4C-alkyl,
- R2 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,
- R3 is hydrogen, halogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkyl, 1-4C-alkylcarbonyl-N-1-4C-alkylamino or the group -CO-NR31R32, where

R31 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and

R32 is hydrogen or 1-4C-alkyl, or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, hydroxypyrrolidino, aziridino, azetidino, piperidino, piperazino, N-1-4C-alkylpiperazino or morpholino group,

R4 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, trifluoromethyl, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonylamino or 1-4C-alkoxy-1-4C-alkoxycarbonylamino,

R5 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

5. (Previously presented) A compound of formula 1a according to claim 4,

- R1 is 1-4C-alkyl, 3-7C-cycloalkyl or fluoro-1-4C-alkyl,
- R2 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,
- R3 is hydrogen, carboxyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-

alkylcarbonyl-N-1-4C-alkylamino or the group -CO-NR31R32,

where

R31 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkyl and

R32 is hydrogen or 1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, aziridino, azetidino or morpholino group,

R4 is hydrogen,

R5 is hydrogen and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

6. (Previously presented) A compound of formula 1a according to claim 4,

in which

R1 is 1-4C-alkyl, 3-7C-cycloalkyl or fluoro-1-4C-alkyl,

R2 is 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,

R3 is carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alko

alkyl, 1-4C-alkylcarbonyl-N-1-4C-alkylamino or the group -CO-NR31R32,

where

R31 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkyl and

R32 is hydrogen or 1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, hydroxypyrrolidino, aziridino, azetidino or morpholino group,

R4 is hydrogen,

R5 is hydrogen and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

7. (Previously presented) A compound of the formula 1a according to claim 4,

in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl,

R3 is hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32,

where

R31 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl or 1-4C-alkyl alkoxy-2-4C-alkyl and

R32 is hydrogen,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino group,

R4 is hydrogen,

R5 is hydrogen and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

8. (Previously presented) A compound of formula 1a according to claim 4,

in which

R1 is 1-4C-alkyl or fluoro-1-4C-alkyl,

R2 is 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,

is carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32,

where

R31 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl or 1-4C-alkyl-alkyl and

R32 is hydrogen or 1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino or morpholino group,

R4 is hydrogen,

R5 is hydrogen and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

9. (Previously presented) A compound according to claim 1, characterized by the formula 2,

$$R3$$
 $R1$
 $R1$
 $R5$
 $R4$
 $R2$
 $R1$
 $R2$
 $R2$
 $R2$
 $R1$
 $R2$
 $R2$
 $R2$
 $R2$
 $R3$
 $R4$

in which

R1 is 1-4C-alkyl or 3-7C-cycloalkyl,

R2 is hydrogen or 1-4C-alkyl,

R3 is 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32,

where

R31 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkyl and

R32 is hydrogen or 1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, aziridino, azetidino or morpholino group,

R4 is hydrogen,

R5 is hydrogen and

X is O (oxygen) or NH,

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

10. (Previously presented) A compound of formula 2 according to claim 9,

- R1 is 1-4C-alkyl, 3-7C-cycloalkyl or fluoro-1-4C-alkyl,
- R2 is 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,
- R3 is carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy-1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonyl-N-1-4C-alkylamino or the group -CO-NR31R32,

where

R31is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkyl and

R32 is hydrogen or 1-4C-alkyl,

or where

R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyrrolidino, hydroxypyrrolidino, aziridino, azetidino or morpholino group,

- R4 is hydrogen,
- R5 is hydrogen and
- X is O (oxygen) or NH,
- or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.
- 11. (Previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 and/or a

pharmacologically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof together with a pharmaceutically acceptable auxiliary and/or excipient.

12. (Canceled)

- 13. (Previously presented) A method of preventing or treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound as claimed in claim 1 or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.
- 14. (Previously presented) A compound of formula 1 according to claim 1 selected from the group consisting of (8S)-2,3-dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-d]imidazole-5-carboxylic acid dimethylamide,
- (8S) -2-methyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid dimethylamide oxalate, and
- (8S)-2,3-dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid methylamide.

15. (New) A compound of the general formula 2,

$$R3$$
 $R1$
 $R1$
 $R5$
 $R4$
 $R2$
 $R1$
 $R2$
 $R1$
 $R2$
 $R1$
 $R2$
 $R1$

in which the substituents R1, R2, R3, R4, R5 and X have the meanings given in the following table, whereby Me is CH_3 and Et is C_2H_5

R1	R2	R3	R4	R5	X
Me	Me	CH ₂ OH	Н	Н	0
Me	Me	CH ₂ OCH ₃	Н	Н	0
Me	Me	CONHMe	Н	Н	0
Me	Me	CON-pyrrolidine	Н	Н	0
Me	Me	CONH (CH ₂) ₂ OH	Н	Н	0
Me	Me	CONH (CH ₂) ₂ OMe	Н	H	0
Me	Me	CONH ₂	Н	Н	0
Me	Me	CON-morpholine	Н	Н	0
Me	Me	CONMe ₂	Н	H	0
Me	Me	CH ₂ O (CH ₂) ₂ OMe	Н	H	0
Me	Me	CON-aziridine	·H	Н	0
Me	Me	COOEt	Н	Н	0
Me	Me	СООН	Н	Н	0
Me	Me	CON-azetidine	Н	H	0
Me	Me	CONH (CH ₂) ₂ Me	Н	Н	0
Me	Me	CONHCH2CHOHCH2OH	H	Н	0
Me	Me	NCH ₃ COCH ₃	Н	Н	0
Me	Me	NHCOCH ₃	Н	Н	0
Me	Me	NHCOCH ₂ OMe	Н	Н	0
Me	Me	NHCO (CH ₂) ₂ OMe	Н	Н	0
Me	Me	OCH ₂ OMe	Н	Н	0
Me	Me	O(CH ₂) ₂ OMe	Н	Н	0
Me	Me	CONH-cyclopropyl	Н	Н	0

R1	R2	R3	R4	R5	х
Me	Me	H	H	H	0
Cyclopropyl	Me	CH ₂ OCH ₃	H	Н	0
Cyclopropyl	Ме	CONHMe	H	H	0
Cyclopropyl	Me Me	CON-pyrrolidine	H	H	0
Cyclopropyl	Ме	CON-PYTIOTICINE CONH (CH ₂) ₂ OH	Н	Н	0
Cyclopropyl	Me	CONH (CH ₂) ₂ OMe	Н	Н	0
Cyclopropyl	Me	CONH (CH ₂) 20ME	H	Н	0
Cyclopropyl	Me	CON-morpholine	H	Н	0
Cyclopropyl	Me	CON-morphorine CONMe ₂	H	H	0
Cyclopropyl	Ме	CH ₂ O (CH ₂) ₂ OMe	H	Н	0
Cyclopropyl	Me	CON-aziridine	H	H	0
	Me	COOEt	H	H	0
Cyclopropyl	Ме	COOEC		_	0
Cyclopropyl			H	H	
Cyclopropyl	Me	CONT. (CIL.) Ma	H	H	0
Cyclopropyl	Me	CONH (CH ₂) ₂ Me	H	H	0
Cyclopropyl	Me	CONHCH2CHOHCH2OH	H	H	0
Cyclopropyl	Me	NCH ₃ COCH ₃	H	H	0
Cyclopropyl	Me	NHCOCH ₃		H	
Cyclopropyl	Me	NHCOCH ₂ OMe	H	H	0
Cyclopropyl	Me	NHCO (CH ₂) ₂ OMe	H	H	0
Cyclopropyl	Me	OCH ₂ OMe	Н	H	0
Cyclopropyl	Me	O(CH ₂) ₂ OMe	H	H	0
Cyclopropyl	Me	CONH-cyclopropyl	H	H	0
Cyclopropyl	Me	H	H	H	0.
CF ₃	Me	CH ₂ OCH ₃	H	H	0
CF ₃	Me	CONHMe	H	H	0
CF ₃	Me	CON-pyrrolidine	H	H	0
CF ₃	Me	CONH (CH ₂) ₂ OH	H H	H	0
CF ₃	Me	CONH (CH ₂) ₂ OMe CONH ₂		H H	0
CF ₃	Me Me	CONH ₂ CON-morpholine	H	Н	0
CF ₃	Me	CON-MOIDHOITHE CONMe ₂	Н	Н	0
		CH ₂ O (CH ₂) ₂ OMe			0
CF ₃	Me	CON-aziridine	H H	H	0
CF ₃	Me Me	COOEt	Н	H	0
CF ₃				H	0
CF ₃	Me	CON-agetidine	Н	Н	0
CF ₃	Me Me	CON-azetidine CONH(CH ₂) ₂ Me	H	H	0
	Me Me		H	H	0
CF ₃	Ме	CONHCH2CHOHCH2OH	H	Н	0
CF ₃	Me	NCH ₃ COCH ₃ NHCOCH ₃	H	H	0
CF ₃	Me	NHCOCH ₂ OMe	H	H	0
CF ₃	Me	NHCO (CH ₂) ₂ OMe	Н	Н	0
CF ₃	Me	OCH ₂ OMe	H	Н	0
CF ₃	Me	O (CH ₂) ₂ OMe	Н	Н	0
CF ₃	ме .Ме	CONH-cyclopropyl	Н	H	0
CF ₃	Me	H CONH-CYCTOPTOPY1	Н	Н	0
Me .	Me CH₂OMe	CH ₂ OCH ₃	Н	H	0
Me	CH ₂ OMe CH ₂ OMe	CONHMe	Н	Н	0
Me	CH ₂ OMe CH ₂ OMe	CONAME CON-pyrrolidine	H	H	0
Me	CH ₂ OMe	CON-PYTTOTIGINE CONH (CH ₂) ₂ OH	Н	Н	0
Me	CH ₂ OMe	CONH (CH ₂) ₂ OMe	H	H	0
	01120116			++	∟

R1	R2	R3	R4	R5	х
Me	CH₂OMe	CONH ₂	Н	Н	0
Me	CH ₂ OMe	CON-morpholine	Н	Н	0
Me	CH ₂ OMe	CONMe ₂	Н	Н	0
Me .	CH₂OMe	CH ₂ O (CH ₂) ₂ OMe	Н	Н	0
Me	CH₂OMe	CON-aziridine	Н	Н	0
Me	CH₂OMe	COOEt	Н	Н	0
Me	CH₂OMe	СООН	Н	Н	0
Ме	CH₂OMe	CON-azetidine	Н	Н	0
Me	CH ₂ OMe	CONH (CH ₂) ₂ Me	Н	Н	0
Ме	CH₂OMe	CONHCH2CHOHCH2OH	Н	Н	0
Me ·	CH ₂ OMe	NCH ₃ COCH ₃	Н	Н	0
Me	CH₂OMe	NHCOCH ₃	Н	Н	0
Me	CH ₂ OMe	NHCOCH ₂ OMe	Н	Н	0
Me	CH ₂ OMe	NHCO (CH ₂) 2OMe	Н	Н	0
Me	CH ₂ OMe	OCH ₂ OMe	Н	Н	0
Me ·	CH₂OMe	O(CH ₂) ₂ OMe	Н	Н	0
Me	CH ₂ OMe	CONH-cyclopropyl	Н	Н	0.
Me	CH ₂ OMe	Н	Н	Н	0
Ме	Н	CH ₂ OCH ₃	Н	Н	0
Me	Н	CONHMe	Н	Н	0
Me	Н	CON-pyrrolidine	Н	Н	0
Me	Н	CONH (CH ₂) ₂ OH	Н	Н	0
Me	Н	CONH (CH ₂) ₂ OMe	Н	Н	0
Me	Н	CONH ₂	Н	Н	0
Me	Н	CON-morpholine	Н	Н	0
Me	Н	CONMe ₂	Н	Н	0
Me	Н	CH ₂ O (CH ₂) ₂ OMe	Н	Н	0
Me	H	CON-aziridine	Н	Н	0
Me	Н	COOEt	Н	Н	0
Ме	Н	СООН	Н	Н	0
Me	H	CON-azetidine	Н	Н	0
Me	Н	CONH (CH ₂) ₂ Me	Н	Н	0
Me	Н	CONHCH2CHOHCH2OH	Н	Н	0
Ме	Н	NCH ₃ COCH ₃	Н	Н	0
Me	H	NHCOCH ₃	Н	Н	0
Me	H	NHCOCH ₂ OMe	Н	Н	0
Me	Н	NHCO (CH ₂) ₂ OMe	Н	Н	0
Me	Н	OCH ₂ OMe	Н	Н	0
Me	H	O(CH ₂) ₂ OMe	Н	Н	0
Me	H	CONH-cyclopropyl	Н	Н	0
Me	H	Н	Н	H .	0
Me	Me	Н	Н	Н	NH
Cyclopropyl	Me	CH ₂ OCH ₃	Н	Н	NH
Cyclopropyl	Me	CONHMe	Н	Н	NH
Cyclopropyl	Me	CON-pyrrolidine	Н	Н	NH
Cyclopropyl	Me	CONH (CH ₂) ₂ OH	Н	Н	NH
Cyclopropyl	Me	CONH (CH ₂) 2OMe	Н	Н	NH
Cyclopropyl	Me	CONH ₂	Н	Н	NH
Cyclopropyl	Me	CON-morpholine	Н	Н	NH
Cyclopropyl	Me	CONMe ₂	Н	Н	NH
Cyclopropyl	Ме	CH ₂ O (CH ₂) ₂ OMe	H	H	NH
Cyclopropyl	Ме	CON-aziridine	Н	H	NH

R1	R2	R3	R4	R5	х
Cyclopropyl	Me	COOEt	Н	Н	NH
Cyclopropyl	Me	СООН	Н	Н	NH
Cyclopropyl	Me.	CON-azetidine	Н	Н	NH
Cyclopropyl	Me	CONH (CH ₂) ₂ Me	Н	н	NH
Cyclopropyl	Me	CONHCH2CHOHCH2OH	Н	Н	NH
Cyclopropyl	Me	NCH ₃ COCH ₃	Н	Н	NH
Cyclopropyl	Me	NHCOCH ₃	Н	Н	NH
Cyclopropyl	Me	NHCOCH₂OMe	Н	Н	NH
Cyclopropyl	Me	NHCO (CH ₂) 2OMe	Н	Н	NH
Cyclopropyl	Me	OCH ₂ OMe	Н	Н	NH
Cyclopropyl	Me	O(CH ₂) ₂ OMe	Н	Н	NH
Cyclopropyl	Me	CONH-cyclopropyl	Н	Н	NH
Cyclopropyl	Me	Н	Н	Н	NH
CF ₃	Me	CH ₂ OCH ₃	Н	Н	NH
CF ₃	Me	CONHMe	Н	Н	NH
CF ₃	Me	CON-pyrrolidine	Н	Н	NH
CF ₃	Me	CONH (CH ₂) ₂ OH	Н	Н	NH
CF ₃	Ме	CONH (CH ₂) 2OMe	Н	Н	NH
CF ₃	Me	CONH ₂	Н	H	NH
CF ₃	Me	CON-morpholine	Н	H	NH
. CF ₃	Me	CONMe ₂	H	H	NH
CF ₃	Me	CH ₂ O (CH ₂) ₂ OMe	Н	H	NH
CF ₃	Me	CON-aziridine	H	Н	NH
CF ₃	Me	COOEt	H	H	NH
CF ₃	Me	СООН	Н	Н	NH
CF ₃	Me	CON-azetidine	Н	Н	NH
CF ₃	Me	CONH (CH ₂) ₂ Me	Н	Н	NH
CF ₃	Ме	CONHCH2CHOHCH2OH	Н	Н	NH
CF ₃	Ме	NCH3COCH3	Н	Н	NH
CF ₃	Me	NHCOCH ₃	Н	Н	NH
CF ₃	Me	NHCOCH₂OMe	Н	Н	NH
CF ₃	Me	NHCO (CH ₂) 2OMe	Н	Н	NH
CF ₃	Me	OCH ₂ OMe	Н	Н	NH
CF ₃ .	Me	O(CH ₂) ₂ OMe	Н	Н	NH
CF ₃	Me	CONH-cyclopropyl	Н	Н	NH
CF ₃	Me	Н	Н	Н	NĤ
Me	CH ₂ OMe	CH ₂ OCH ₃	Н	Н	NH
Me	CH ₂ OMe	CONHMe	Н	Н	NH
Me	CH₂OMe	CON-pyrrolidine	н	Н	NH
Me	CH ₂ OMe	CONH (CH ₂) ₂ OH	Н	Н	NH
Me	CH ₂ OMe	CONH (CH ₂) ₂ OMe	Н	H	NH
Me	CH ₂ OMe	CONH ₂	Н	н	NH
Me	CH₂OMe	CON-morpholine	Н	Н	NH
Me	CH ₂ OMe	CONMe ₂	Н	Н	NH
Me	CH ₂ OMe	CH ₂ O (CH ₂) ₂ OMe	Н	Н	NH
Ме	CH ₂ OMe	CON-aziridine	Н	Н	NH
Me	CH ₂ OMe	COOEt	Н	Н	NH
Me	CH ₂ OMe	СООН	Н	Н	NH
Ме	CH₂OMe	CON-azetidine	Н	H	NH
Me	CH₂OMe	CONH (CH ₂) ₂ Me	Н	Н	NH
Ме	CH ₂ OMe	CONHCH2CHOHCH2OH	Н	Н	NH
Me	CH₂OMe	NCH ₃ COCH ₃	Н	Н	NH

R1	R2	R3	R4	R5	X
Me	CH ₂ OMe	NHCOCH ₃	Н	Н	NH
Me	CH ₂ OMe	NHCOCH₂OMe	Н	Н	NH
Me	CH ₂ OMe	NHCO (CH ₂) ₂ OMe	Н	Н	NH
Me	CH ₂ OMe	OCH ₂ OMe	Н	Н	NH
Me	CH ₂ OMe	O(CH ₂) ₂ OMe	Н	Н	NH
Me	CH₂OMe	CONH-cyclopropyl	Н	Н	NH
Me	CH ₂ OMe	Н	Н	Н	NH
Me	H	CH ₂ OCH ₃	Н	Н	NH
Me	H	CONHMe	Н	Н	NH
Me	Н	CON-pyrrolidine	Н	Н	NH
Me	H	CONH (CH ₂) ₂ OH	H	Н	NH
Me	Н	CONH (CH ₂) ₂ OMe	Н	H	NH
Me	H	CONH ₂	Н	Н	NH
Me	H	CON-morpholine	Н	Н	NH
Me	Н	CONMe ₂	Н	Н	NH
Me ·	Н	CH ₂ O (CH ₂) ₂ OMe	Н	H	NH
Me	H	CON-aziridine	H	H	NH
Me	H	COOEt	Н	Н	NH
Me	Н	СООН	Н	Н	NH
Me ·	H	CON-azetidine	Н	Н	NH
Me	Н	CONH (CH ₂) ₂ Me	Н	Н	NH
Me	Н	CONHCH2CHOHCH2OH	Н	Н	NH
Me	H	NCH3COCH3	Н	Н	NH
Me	H	NHCOCH ₃	Н	Н	NH
Me	Н	NHCOCH₂OMe	Н	Н	NH
Me	Н	NHCO (CH ₂) ₂ OMe	Н	Н	NH
Ме	H	OCH ₂ OMe	Н	Н	NH
Me	Н	O(CH ₂) ₂ OMe	Н	Н	NH
Ме	Н	CONH-cyclopropyl	Н	Н	NH
Me	Н	H	Н	Н	NH

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

- 16. (New) A compound according to claim 1 which is selected from the group consisting of
- ${\tt 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[7,8-tetrahydro-chromeno[8,8-tetrahydro-chromeno$
- a]imidazole- 5-carboxylic acid dimethylamide,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-
- h]quinoline-5-carboxylic acid dimethylamide,

```
2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
```

- d]imidazole-5-carboxylic acid amide,
- 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid methylamide,
- 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid (2-hydroxy-ethyl)-amide,
- 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid (2-methoxy-ethyl)-amide,
- 1-(2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazol-5-yl)-1-morpholin-4-yl-methanone,
- 1-(2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazol-5-yl)-1-pyrrolidin-1-yl-methanone,
- 2-Isopropyl-3-methyl-8-phenyl-3,6,7,8-tetrahydro-
- chromeno[7,8-d]imidazole-5-carboxylic acid dimethylamide,
- 2-Cyclopropyl-3-methyl-8-phenyl-3,6,7,8-tetrahydro-
- chromeno[7,8-d]imidazole-5-carboxylic acid dimethylamide,
- 5-Methoxymethyl-2,3-dimethyl-8-phenyl-3,6,7,8-tetrahydro-
- chromeno[7,8-d]imidazole oxalic acid,
- 5-(2-Methoxy-ethoxymethyl)-2,3-dimethyl-8-phenyl-3,6,7,8-
- tetrahydro-chromeno[7,8-d]-imidazole oxalic acid,
- 1-Aziridin-1-yl-1-(2,3-dimethyl-8-phenyl-3,6,7,8-
- tetrahydro-chromeno [7,8-d] imidazol-5-yl) -methanone,

```
3-Methyl-8-phenyl-2-trifluoromethyl-3,6,7,8-tetrahydro-
chromeno[7,8-d]imidazole-5-carboxylic acid dimethylamide,
2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazole-5-carboxylic acid ethyl ester,
2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazole-5-carboxylic acid,
(2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazol-5-yl)-methanol,
1-Azetidin-1-yl-1-(2,3-dimethyl-8-phenyl-3,6,7,8-
tetrahydro-chromeno [7,8-d] imidazol-5-yl) -methanone,
2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazole-5-carboxylic acid propyl-amide,
1-(2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazol-5-yl)-1-(3-hydroxy-pyrrolidin-1-yl)-methanone,
2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazole-5-carboxylic acid (2,3-dihydroxy-propyl)-amide,
3-Methoxymethyl-2-methyl-8-phenyl-3,6,7,8-tetrahydro-
chromeno[7,8-d]imidazole-5-carboxylic Acid Dimethylamide,
N-(2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazol-5-yl)-N-methyl-acetamide,
2-Ethyl-3-methyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
d]imidazole-5-carboxylic acid dimethylamide,
```

- Ethyl 2,3-dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline-5-carboxylate,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline-5-carboxylic acid,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-
- h]quinoline-5-carboxylic acid 2-hydroxy-ethylamide,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-
- h]quinoline-5-carboxylic acid amide,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-
- h]quinoline-5-carboxylic acid methylamide,
- 2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-
- h]quinoline-5-carboxylic acid 1-aziridinyl-amide,
- 5-Hydroxymethyl-2,3-dimethyl-8-phenyl-6,7,8,9-tetrahydro-
- 3H-imidazo[4,5-h]quinoline,
- (8S) and (8R) -2,3-Dimethyl-8-phenyl-6,7,8,9-tetrahydro-3H-
- imidazo[4,5-h]quinoline-5-carboxylic acid methylamide,
- (8S) -2, 3-Dimethyl-8-phenyl-3, 6, 7, 8-tetrahydro-chromeno [7, 8-
- d]imidazole-5-carboxylic acid dimethylamide,
- (8R) -2, 3-Dimethyl-8-phenyl-3, 6, 7, 8-tetrahydro-chromeno [7, 8-
- d]imidazole-5-carboxylic acid dimethylamide,
- 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid cyclopropyl-amide,

- 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole,
- 2-Methyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid dimethylamide,
- (S)-2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-
- d]imidazole-5-carboxylic acid dimethylamide,

and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.